Advocacy intelligence hub — real-time data for patient organizations
Uppsala University — NA
National Cancer Center, Korea — PHASE2
Exelixis — PHASE2, PHASE3
University of Chicago — PHASE1
National Cancer Institute (NCI) — PHASE1
Azienda Ospedaliera Universitaria Integrata Verona
IRCCS San Raffaele
Fudan University — NA
Changhai Hospital — PHASE2
David Bushnell — EARLY_PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Chirostim
ChiRhoClin, Inc.
CABOMETYX
(cabozantinib)Orphan drugstandardExelixis, Inc.
12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-...
Secreflo
(Synthetic porcine secretin)Orphan drugstandardChiRhoClin, Inc.
Everolimus
(EVEROLIMUS)Orphan drugstandardBreckenridge Pharmaceutical, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pat...
Diane Reidy-Lagunes, MD,MS, MD, MS
Memorial Sloan Kettering Cancer Center
📍 NEW YORK, NY
Saleh K Saleh, MD
Minia University
📍 Minya, Minya Governorate
Annamaria Colao, MD, PhD
University Federico II of Naples
Aung Naing
M.D. Anderson Cancer Center
Study Official
Genmab
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)